Animal Health
We think small so you can work big
How Nanocin is advancing drug reformulation in animal health
Nanocin is an innovative new drug reformulation platform, being the only platform of its type that is fully translatable from the lab to the clinic.
Because of its unique nanotechnology, Nanocin offers enormous potential for significant improvements in drug efficiency and targeted delivery. The traditional route of drug development for companion animals typically spans 6.5 years and demands an investment of $22.5 million, while livestock pharmaceuticals extend this timeline to 8.5 years and require $30.5 million on average. These expenses, which may escalate to $62 million, exhibit an upward trend annually, emphasizing the need for pharmaceutical companies to explore innovative and cost-effective approaches to drug development.
Reforming or repositioning existing drug formulations represents a low risk and cost-efficient methods and a solution to this problem – but only with the right tools.
Nanocin: realising the potential in reformulation
Nanocin forms nanoparticles with a huge range of molecular and drug cargos, including DNA, RNA, small molecules, proteins, peptides, and natural products.
This formulation significantly enhances the ability of the nanoparticles to penetrate into cells and tissue, leading to improved and more targeted drug delivery.
Custom built to support drug development
Specifically designed for drug formulation and bioprocessing, Nanocin GMP is a delivery tool with an exceptional safety profile.
Its core polymer has a long-established safety track record and is found in a range of human health and wellbeing products, from eye drops to hand wash.
To bring this nanotechnology to patients across a range of settings, Tecrea has a number of partnerships already in place with both large and small pharma companies.
Through past partnerships, our technology platform is used under licence in several areas of animal health, including:
- Otitis externa
- Mastitis
- Endometriosis
In every collaboration, we typically follow a structured pipeline to ensure the success of the product. However, since each product has unique characteristics, we meticulously tailor our approach accordingly, considering these distinct attributes during the formulation development and testing phases. As a result, the sequence in which we execute each step may vary. The standard pipeline is as follows:
|
Feasibility studies
|
Feasibility studies
The first phase is always composed of feasibility studies, which are aimed at assessing the project's viability. These studies enable us to guide our clients towards informed formulation decisions, minimizing the likelihood of clinical setbacks. Throughout this phase, and after meticulous study and analysis, we develop possible drug formulations and conduct preliminary tests on these until we achieve a successful outcome on a small scale.
|
|
|
|
Stability studies
|
Stability studies
Following the formulation's development, we rigorously assess its quality and performance across various environmental conditions to ensure both its efficacy and reliability. This meticulous evaluation process guarantees that the drug meets quality standards, delivering consistent effectiveness and reproducibility under diverse circumstances.
|
|
|
|
Characterization studies
|
Characterization studies
We verify the presence of the anticipated drug concentration in the formulation while assessing its chemical stability. Additionally, we ensure that the drug maintains its functionality and that Nanocin retains its antimicrobial activity if required. This process often includes in vitro tests, which are especially critical in the early phases of drug reformulation. These tests are essential to confirm the effectiveness of the drug formulation we have developed.
|
|
|
|
Scalability studies
|
Scalability studies
Scalability tests are performed to determine the feasibility of upscaling the formulation for manufacturing purposes. These studies involve replicating stability in large scale to ensure that the product can be manufactured reliably and efficiently while maintaining its quality and efficacy.
|
|
|
|
In vivo studies
|
In vivo studies
The final phase entails in vivo testing, where the effects of the drugs are evaluated on whole, living organisms or cells, with a particular focus on the intended population for which the drug is being reformulated. While typically the responsibility of the company, we also offer expertise in overseeing this critical step if needed.
|
|
Our specialty lies in overcoming your development challenges by effectively solving problems and saving time. We collaborate with you to thoroughly comprehend your product needs and develop the best possible formulation.
As a cutting-edge and highly cost-effective tool, Nanocin GMP represents an opportunity for new commercial pharmaceutical partners to collaborate with Tecrea.
Talk to our scientists (info@tecrea.com) about how to become a partner and take advantage of Tecrea’s innovative nanotechnology.